Market Size of Infectious Disease Diagnostics Industry
Study Period | 2019 - 2029 |
Market Size (2024) | USD 45.24 Billion |
Market Size (2029) | USD 53.68 Billion |
CAGR (2024 - 2029) | 3.48 % |
Fastest Growing Market | Asia Pacific |
Largest Market | North America |
Major Players*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Infectious Disease Diagnostics Market Analysis
The Infectious Disease Diagnostics Market size is estimated at USD 45.24 billion in 2024, and is expected to reach USD 53.68 billion by 2029, growing at a CAGR of 3.48% during the forecast period (2024-2029).
The market for infectious illness diagnostics was considerably affected by the COVID-19 pandemic. The market under study benefited from the high infection rates among COVID-19 patients. For instance, in February 2022, Mylab Discovery Solutions released CoviSwift, a point-of-care (POC) RT-PCR testing system that may be used in small labs, in-hospital labs, airports, and communities. Additionally, in March 2020, BioMedomics released PoC COVID-19 test that can detect antibodies in blood within 15 minutes. Furthermore, in March 2020, Abbott introduced the RealTime SARS-CoV-2 assay, a PCR-based test for diagnosing COVID-19. As the incidence of coronavirus increased, there was a greater need for diagnostic tools for infectious diseases during the pandemic. Additionally, many diagnostic labs and testing facilities opened, which broadened the market's potential. For instance, in June 2020, the Union Minister of Health and Family Welfare introduced India's first mobile I-Lab (Infectious disease diagnostic lab) for COVID-19 testing. Hence, in the early phase, COVID-19 impacted the market considerably; however, currently, the demand for diagnostic tools for infectious diseases has slowed down and is expected to have stable growth during the forecast period of the study.
The rising prevalence of infectious diseases, the shift in emphasis from centralized laboratories to point-of-care testing, and rising R&D activity on infectious disease diagnostics are other important drivers of market expansion. Rapid diagnostics for the detection of diseases are evolving as a result of scientific research and development efforts in developing novel technologies and techniques, including mass spectrometry and next-generation sequencing (NGS), fueling market expansion. For instance, according to an article by Frontiers in February 2022, non-typhoidal Salmonella is a common cause of bacterial enteritis in humans. It causes almost 93.8 million cases of gastroenteritis globally each year. The increasing preference of end users for point-of-care testing is also projected to fuel market expansion. Point-of-care diagnostics offer quick, useful information for patient care where the disease is being experienced. As a result, several firms are concentrating on research and development initiatives to create point-of-care diagnostic solutions for developing nations. The major firms are constantly updating their product lines through introducing new goods, joint ventures with third parties, mergers, and acquisitions, all of which will contribute to the worldwide study market's expansion. For instance, in December 2021, Roche launched the first infectious disease tests on the Cobas 5800 System, a new molecular laboratory instrument, in countries accepting the CE mark. Similarly, in May 2021, Torus Biosystems revealed the USD 25 million series financing to advance infectious disease diagnostics across healthcare settings.
Thus, factors such as the rising prevalence of infectious diseases and increasing initiatives by major market players are expected to drive market growth over the forecast period. However, inadequate reimbursements and rising healthcare costs limiting the use of novel diagnostic techniques are restraining the market's growth.
Infectious Disease Diagnostics Industry Segmentation
As per the scope of the report, infectious disease diagnostics involve identifying the presence of foreign antigens/organisms using diagnostic tools such as kits and devices.
The Infectious Disease Diagnostics Market is segmented by application (Bacterial Infection, Cardiovascular Infection, CNS Infections, fungal Infection, Gastrointestinal Infection, Sexually Transmitted Disease, Viral Infection, and Other Applications), product (Assays, Kits, and Reagents, Instruments, and Services and Software), technology (Polymerase Chain Reaction (PCR), Isothermal Nucleic Acid Amplification Technology (INAAT), immunodiagnostics, DNA microarray, clinical microbiology, DNA sequencing and next-generation sequencing (NGS), and other technologies), and geography (North America, Europe, Asia-Pacific, Middle East, and Africa, and South America). The report offers the value (in USD million) for the above segments.
By Application | |
Hepatitis | |
Human Immunodeficiency Virus (HIV) | |
Chlamydia Trachomatis Genital Infection and Gonorrhea (CT/NG) | |
Hospital-acquired Infections | |
Human Papillomavirus (HPV) | |
Tuberculosis (TB) | |
Influenza | |
Other Infectious Diseases |
By Product | |
Assays, Kits, and Reagents | |
Instruments | |
Services and Software |
By Technology | |
Polymerase Chain Reaction (PCR) | |
Isothermal Nucleic Acid Amplification Technology (INAAT) | |
Immunodiagnostics | |
DNA Microarray | |
Clinical Microbiology | |
DNA Sequencing and Next-Generation Sequencing (NGS) | |
Other Technologies |
Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Infectious Disease Diagnostics Market Size Summary
The infectious disease diagnostics market is poised for steady growth over the forecast period, driven by several key factors. The market experienced a significant boost during the COVID-19 pandemic, which highlighted the critical need for advanced diagnostic tools. This led to the rapid development and deployment of various testing solutions, such as point-of-care RT-PCR systems and antibody tests. The pandemic also spurred the establishment of numerous diagnostic labs and testing facilities, expanding the market's potential. However, as the demand for COVID-19 diagnostics stabilizes, the market is expected to grow at a consistent pace, supported by the rising prevalence of infectious diseases and a shift towards point-of-care testing. Technological advancements in rapid diagnostics, including mass spectrometry and next-generation sequencing, are further propelling market expansion. Major players are actively investing in research and development to enhance diagnostic solutions, particularly in developing regions, through new product launches and strategic partnerships.
The market's growth is also influenced by the increasing prevalence of diseases such as HIV, which is driving demand for diagnostic tests. Initiatives by organizations to raise awareness and improve testing accessibility are expected to support market expansion. North America is anticipated to hold a significant market share, fueled by high healthcare expenditure and increased awareness of diagnostic devices. Strategic activities, including collaborations and grant programs, are further enhancing market growth in the region. The market is characterized by fragmentation, with numerous global players employing various growth strategies to strengthen their presence. Key companies are focusing on product innovation and geographical expansion to capture a larger market share. Despite challenges such as inadequate reimbursements and rising healthcare costs, the market is set to grow, driven by technological advancements and strategic initiatives by major players.
Infectious Disease Diagnostics Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Increasing Prevalence of Infectious Diseases
-
1.2.2 Shift in Focus from Centralized Laboratories to Decentralized Point-of-Care Testing
-
1.2.3 Research on Infectious Disease Diagnostics
-
-
1.3 Market Restraints
-
1.3.1 Inadequate Reimbursements
-
1.3.2 Rising Healthcare Costs Limiting the Use of Novel Diagnostic Techniques
-
-
1.4 Porter's Five Forces Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION (Market Size By Value- USD million)
-
2.1 By Application
-
2.1.1 Hepatitis
-
2.1.2 Human Immunodeficiency Virus (HIV)
-
2.1.3 Chlamydia Trachomatis Genital Infection and Gonorrhea (CT/NG)
-
2.1.4 Hospital-acquired Infections
-
2.1.5 Human Papillomavirus (HPV)
-
2.1.6 Tuberculosis (TB)
-
2.1.7 Influenza
-
2.1.8 Other Infectious Diseases
-
-
2.2 By Product
-
2.2.1 Assays, Kits, and Reagents
-
2.2.2 Instruments
-
2.2.3 Services and Software
-
-
2.3 By Technology
-
2.3.1 Polymerase Chain Reaction (PCR)
-
2.3.2 Isothermal Nucleic Acid Amplification Technology (INAAT)
-
2.3.3 Immunodiagnostics
-
2.3.4 DNA Microarray
-
2.3.5 Clinical Microbiology
-
2.3.6 DNA Sequencing and Next-Generation Sequencing (NGS)
-
2.3.7 Other Technologies
-
-
2.4 Geography
-
2.4.1 North America
-
2.4.1.1 United States
-
2.4.1.2 Canada
-
2.4.1.3 Mexico
-
-
2.4.2 Europe
-
2.4.2.1 Germany
-
2.4.2.2 United Kingdom
-
2.4.2.3 France
-
2.4.2.4 Italy
-
2.4.2.5 Spain
-
2.4.2.6 Rest of Europe
-
-
2.4.3 Asia-Pacific
-
2.4.3.1 China
-
2.4.3.2 Japan
-
2.4.3.3 India
-
2.4.3.4 Australia
-
2.4.3.5 South Korea
-
2.4.3.6 Rest of Asia-Pacific
-
-
2.4.4 Middle East and Africa
-
2.4.4.1 GCC
-
2.4.4.2 South Africa
-
2.4.4.3 Rest of Middle East and Africa
-
-
2.4.5 South America
-
2.4.5.1 Brazil
-
2.4.5.2 Argentina
-
2.4.5.3 Rest of South America
-
-
-
Infectious Disease Diagnostics Market Size FAQs
How big is the Infectious Disease Diagnostics Market?
The Infectious Disease Diagnostics Market size is expected to reach USD 45.24 billion in 2024 and grow at a CAGR of 3.48% to reach USD 53.68 billion by 2029.
What is the current Infectious Disease Diagnostics Market size?
In 2024, the Infectious Disease Diagnostics Market size is expected to reach USD 45.24 billion.